John F. Ginascol
Net Worth

Last updated:

What is John F. Ginascol net worth?

The estimated net worth of Mr. John F. Ginascol is at least $31,873,916 as of 1 Mar 2023. He owns shares worth $15,568,154 as insider, has earned $7,905,762 from insider trading and has received compensation worth at least $8,400,000 in Abbott Laboratories.

What is the salary of John F. Ginascol?

Mr. John F. Ginascol salary is $1,680,000 per year as Executive Vice President of Core Diagnostics in Abbott Laboratories.

How old is John F. Ginascol?

Mr. John F. Ginascol is 66 years old, born in 1959.

What stocks does John F. Ginascol currently own?

As insider, Mr. John F. Ginascol owns shares in one company:

Company Title Shares Price per share Total value
Abbott Laboratories (ABT) Executive Vice President of Core Diagnostics 118,380 $131.51 $15,568,154

What does Abbott Laboratories do?

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

ABT logo
ABT
Abbott Laboratories
$131.51

John F. Ginascol insider trading

Abbott Laboratories

Mr. John F. Ginascol has made 5 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 943 units of ABT stock worth $94,960 on 1 Mar 2023.

The largest trade he's ever made was exercising 72,098 units of ABT stock on 1 Sep 2020. As of 1 Mar 2023 he still owns at least 118,380 units of ABT stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common shares without par value 943 $100.7 $94,960
Sale
Common shares without par value 11,000 $112.32 $1,235,520
Option
Common shares without par value 45,709 $47 $2,148,323
Option
Option (right to buy) 45,709 $47 $2,148,323
Sale
Common shares without par value 352 N/A N/A
Option
Option (right to buy) 32,145 $42.7 $1,372,592
Option
Common shares without par value 72,098 $43.27 $3,119,464
Option
Option (right to buy) 63,200 $38.4 $2,426,880
Sale
Common shares without par value 63,200 $95.91 $6,061,765
Option
Common shares without par value 63,200 $38.4 $2,426,880
Sale
Common shares without par value 6,606 $77.74 $513,517

Abbott Laboratories key executives

Abbott Laboratories executives and other stock owners filed with the SEC: